Back to Stakeholders
Categories

2 domains / 4 areas / 2 specializations

Johnson & Johnson

Also known as: Johnson & Johnson, Janssen Scientific Affairs, LLC, Janssen Scientific Affairs, Janssen Research & Development, Janssen Pharmaceuticals, Janssen-Cilag, Janssen Pharmaceuticals, Inc., Janssen Korea, Ltd., Korea

Data updated

United States
23 Trials1 Patent

Johnson & Johnson is a publicly traded global healthcare company rather than a venture fund or dedicated asset manager. Its business spans pharmaceuticals and medical technology, and the company is based in New Brunswick, New Jersey, United States.

In the psychedelic ecosystem, Johnson & Johnson matters mainly through its neuroscience and psychiatry-adjacent pharmaceutical activity rather than as a standalone investor. Its acquisition of Intra-Cellular Therapies, a CNS-focused biopharma, shows continued interest in neuropsychiatric therapeutics and related clinical-stage assets.

Academic Research

0 papers

Published Papers

0

Trial Involvement

23

Distinct Focus Topics

0

Latest Publication

Unknown

Investor Context

Institutional Investors

Investment Context

This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development.

Johnson & Johnson is best understood as a strategic corporate healthcare platform with broad exposure to neuroscience, oncology, immunology, and medical technology. It is not a traditional institutional investor, but it does make large strategic acquisitions and operates an internal venture arm through Johnson & Johnson Innovation – JJDC. That combination makes it relevant to psychedelic-adjacent markets where psychiatric, neurological, and clinical-stage drug development intersect with J&J’s core R&D and commercialization strengths.

Investor Type

Institutional Investor

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

Growth / Late StagePublic MarketsMulti-Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Institutional Investor

Investment Website

Quick Facts

Type
Big Pharma
Founded
1886
HQ
United States
Website
Visit

Research Landscape

What the 23 registered trials Johnson & Johnson sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of July 2026.

How fast is Johnson & Johnson research growing?

Sourced

Registered trials by recorded study-start year. Click a year for the running total.

4trials began in 2015

+100% vs 2014

8 started by 2015

Browse trials

Don't read as total research effort: only registered trials with a recorded start date are counted (23 of 23 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.

What's live right now, and what stopped?

Sourced

Registry status of all 23 Johnson & Johnson trials Blossom tracks. Orange marks trials recruiting or opening.

Recruiting or opening
313%
Completed
1670%
Stopped early
313%
Unknown / other
14%

Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.

Sponsored Trials

20

Collaborated Trials

3

Patents

1